Nxera Pharma to Receive $8.6M Milestone Payment from Centessa for OX2R Development
Tokyo, Japan and Cambridge, UK, September 3, 2026 Nxera Pharma announced that Centessa Pharmaceuticals, a wholly owned subsidiary of...
ADC AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Tokyo, Japan and Cambridge, UK, September 3, 2026 Nxera Pharma announced that Centessa Pharmaceuticals, a wholly owned subsidiary of...
SHANGHAI, CHINA, Aug 28, 2026 Duality Biotherapeutics, Inc. (DualityBio) has entered into a global collaboration and license agreement with...
SAN FRANCISCO, USA and SUZHOU, China, August 9, 2026 Innovent Biologics and Daiichi Sankyo have entered into an exclusive...
SAN JOSE, Calif. | July 9, 2026 Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company pioneering oral biologic drug...
TEL AVIV, Israel / ZUG, Switzerland | July 9, 2026 Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical...
SHANGHAI, China and PRINCETON, N.J., May 12, 2026 Hengrui Pharma and Bristol Myers Squibb (BMS) have announced a landmark...
SAN DIEGO and MENLO PARK, Calif., May 6, 2026 Halozyme Therapeutics and Oruka Therapeutics announced a global exclusive collaboration...
WATERTOWN, Mass., April 09, 2026 C4 Therapeutics, Inc. has announced a major expansion of its long-term collaboration with Roche,...
